MARKET

FULC

FULC

Fulcrum Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.76
+0.36
+4.86%
Pre Market: 8.15 +0.39 +5.03% 08:00 08/11 EDT
OPEN
7.66
PREV CLOSE
7.40
HIGH
7.81
LOW
7.45
VOLUME
100
TURNOVER
--
52 WEEK HIGH
33.10
52 WEEK LOW
3.210
MARKET CAP
316.98M
P/E (TTM)
-3.2553
1D
5D
1M
3M
1Y
5Y
BRIEF-Fulcrum Therapeutics Announces Strategic Realignment To Reduce Operating Expenses
BRIEF-Fulcrum Therapeutics Announces Strategic Realignment To Reduce Operating Expenses
Reuters · 1h ago
Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Fulcrum Therapeutics press release (<span class="...
Seekingalpha · 1h ago
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second qua...
GlobeNewswire · 08/04 12:07
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company gr...
GlobeNewswire · 08/02 12:00
Fulcrum Says Phase 3 FSHD Clinical Trial Using AMRA Medical's Whole-body MRI Measurements As Key Secondary Endpoint
https://www.prnewswire.com/news-releases/fulcrum-phase-3-fshd-clinical-trial-using-amra-medicals-whole-body-mri-measurements-as-a-key-secondary-endpoint-301585824.html
Benzinga · 07/13 13:54
Hot Stocks: AAL rises on preliminary revenue; HLF upgrade; ONEM downgrade; FULC slides
With earnings season beginning to ramp up, American Airlines (NASDAQ:AAL<...
Seekingalpha · 07/12 16:54
Sector Update: Health Care Stocks Drop on Tuesday
MT Newswires · 07/12 16:06
Sector Update: Health Care Stocks Drifting Lower This Afternoon
MT Newswires · 07/12 13:09
More
No Data
Learn about the latest financial forecast of FULC. Analyze the recent business situations of Fulcrum Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
50.00%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FULC stock price target is 28.38 with a high estimate of 43.00 and a low estimate of 7.00.
High43.00
Average28.38
Low7.00
Current 7.76
EPS
Actual
Estimate
-0.58-0.44-0.29-0.15
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 118
Institutional Holdings: 39.30M
% Owned: 96.20%
Shares Outstanding: 40.85M
TypeInstitutionsShares
Increased
29
2.38M
New
20
4.10M
Decreased
38
2.60M
Sold Out
22
1.66M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Kate Haviland
President/Chief Executive Officer/Director
Bryan Stuart
Chief Financial Officer
Esther Rajavelu
Corporate Executive
Judith Dunn
General Counsel
Curtis Oltmans
Other
Mel Hayes
Director
Robert Gould
Independent Director
Sonja Banks
Independent Director
James Collins
Independent Director
Katina Dorton
Independent Director
Alan Ezekowitz
Independent Director
James Geraghty
No Data
No Data
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The Company uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).

Webull offers kinds of Fulcrum Therapeutics Inc stock information, including NASDAQ:FULC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FULC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FULC stock methods without spending real money on the virtual paper trading platform.